YTHDC1 and colitis: Administration of TNBS, a haptenating agent, causes an immune response and results in transmural colitis representing clinical Crohn's disease.[27] Here, we confirmed that gut macrophages lacking YTHDC1 benefit colitis progression in both DSS‐ and TNBS‐induced animals, revealing the requirement of YTHDC1 for limiting IBD development.